| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $24,999,993 | 1 | 17 |
Sells | $139,578,705 | 5 | 83 |
| Fairmount Funds Management LLC | director | 1 | $25M | 1 | $127.4M | $-102.4M |
| Kearns Evan | Chief Legal Officer | 0 | $0 | 1 | $2.52M | $-2.52M |
| Green John L. | Chief Financial Officer | 0 | $0 | 1 | $2.98M | $-2.98M |
| Sachs Jessica | Chief Medical Officer | 0 | $0 | 1 | $3.2M | $-3.2M |
| Robinson John Edward | Chief Scientific Officer | 0 | $0 | 1 | $3.49M | $-3.49M |
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Cogent Biosciences, Inc. have bought $25M and sold $139.58M worth of Cogent Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Cogent Biosciences, Inc. have bought $11.21M and sold $69.87M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fairmount Funds Management LLC (director) — $25M.
The last purchase of 2,777,777 shares for transaction amount of $25M was made by Fairmount Funds Management LLC (director) on 2025‑07‑10.
| 2026-01-22 | Sale | Fairmount Funds Management LLC | director | 3.5M 2.1196% | $36.40 | $127.4M | -4.68% | |
| 2025-12-26 | Sale | Robinson John Edward | Chief Scientific Officer | 90,000 0.063% | $38.74 | $3.49M | -5.62% | |
| 2025-12-26 | Sale | Sachs Jessica | Chief Medical Officer | 82,642 0.0577% | $38.70 | $3.2M | -5.62% | |
| 2025-12-26 | Sale | Green John L. | Chief Financial Officer | 77,000 0.0538% | $38.68 | $2.98M | -5.62% | |
| 2025-12-26 | Sale | Kearns Evan | Chief Legal Officer | 65,000 0.0454% | $38.70 | $2.52M | -5.62% | |
| 2025-07-10 | Fairmount Funds Management LLC | director | 2.78M 2.0237% | $9.00 | $25M | +42.58% | ||
| 2025-01-14 | Pinnow Cole | Chief Commercial Officer | 43,750 0.0412% | $7.60 | $332,413 | +48.98% | ||
| 2023-06-09 | Fairmount Funds Management LLC | 10 percent owner | 800,000 0.9139% | $12.00 | $9.6M | -33.60% | ||
| 2022-06-16 | Fairmount Funds Management LLC | 1.2M 0.9424% | $8.25 | $9.9M | +55.51% | |||
| 2021-04-26 | Sale | Green John L. | Chief Financial Officer | 17,813 0.015% | $8.86 | $157,823 | -6.66% | |
| 2020-05-12 | Sale | CAMPANA DARIO | 10 percent owner | 98,200 0.0043% | $0.46 | $45,545 | +429.08% | |
| 2020-05-11 | Sale | CAMPANA DARIO | 10 percent owner | 100,000 0.0043% | $0.46 | $45,496 | +440.83% | |
| 2020-05-08 | Sale | CAMPANA DARIO | 10 percent owner | 100,000 0.0044% | $0.46 | $46,390 | +433.33% | |
| 2020-05-07 | Sale | CAMPANA DARIO | 10 percent owner | 100,000 0.0039% | $0.41 | $41,430 | +482.93% | |
| 2020-05-06 | Sale | CAMPANA DARIO | 10 percent owner | 1,800 <0.0001% | $0.40 | $722 | +524.04% | |
| 2020-05-05 | Sale | CAMPANA DARIO | 10 percent owner | 135,484 0.0052% | $0.40 | $54,437 | +508.44% | |
| 2020-05-04 | Sale | CAMPANA DARIO | 10 percent owner | 4,795 0.0002% | $0.40 | $1,921 | +508.44% | |
| 2020-05-01 | Sale | CAMPANA DARIO | 10 percent owner | 800 <0.0001% | $0.41 | $328 | +506.21% | |
| 2020-04-30 | Sale | CAMPANA DARIO | 10 percent owner | 75,994 0.0029% | $0.40 | $30,557 | +465.99% | |
| 2020-04-29 | Sale | CAMPANA DARIO | 10 percent owner | 382,927 0.0148% | $0.41 | $155,507 | +508.44% |
| Fairmount Funds Management LLC | director | 5503418 3.6194% | $201.87M | 3 | 1 | +55.51% |
| Robinson John Edward | Chief Scientific Officer | 140002 0.0921% | $5.14M | 0 | 1 | |
| Sachs Jessica | Chief Medical Officer | 133938 0.0881% | $4.91M | 0 | 1 | |
| Green John L. | Chief Financial Officer | 131834 0.0867% | $4.84M | 0 | 2 | |
| Kearns Evan | Chief Legal Officer | 109398 0.0719% | $4.01M | 0 | 1 | |
| FROST PHILLIP MD ET AL | 15734874 10.3482% | $577.16M | 6 | 0 | ||
| Schulke Ryan | Chief Executive Officer | 6364537 4.1857% | $233.45M | 9 | 0 | +150.58% |
| Conlin Matthew | President | 4437980 2.9187% | $162.79M | 7 | 0 | +150.58% |
| Booth Bruce | director | 3361535 2.2108% | $123.3M | 1 | 0 | <0.0001% |
| Atlas Venture Fund IX, L.P. | 10 percent owner | 3361535 2.2108% | $123.3M | 1 | 0 | <0.0001% |
| CAMPANA DARIO | 10 percent owner | 3095114 2.0355% | $113.53M | 0 | 21 | |
| Ratcliffe Liam | director | 897773 0.5904% | $32.93M | 1 | 0 | <0.0001% |
| Dubner Derek | Chief Executive Officer | 589513 0.3877% | $21.62M | 4 | 3 | |
| FMR LLC | 452115 0.2973% | $16.58M | 1 | 0 | <0.0001% | |
| Reilly James Patrick | President | 379946 0.2499% | $13.94M | 0 | 3 | |
| Fried Robert N | director | 337338 0.2219% | $12.37M | 1 | 0 | |
| Jordan Harry Baker III | Chief Operating Officer | 110000 0.0723% | $4.03M | 4 | 0 | |
| KIM PAUL | Chief Financial Officer | 50000 0.0329% | $1.83M | 0 | 13 | |
| Pinnow Cole | Chief Commercial Officer | 45848 0.0302% | $1.68M | 1 | 0 | |
| MacLachlan Daniel | Chief Financial Officer | 3500 0.0023% | $128,380.00 | 2 | 3 | |
| BOLGER JOHN C | director | 0 0% | $0 | 1 | 3 | |
| Hsieh Ming | Chief Executive Officer | 0 0% | $0 | 0 | 15 | |
| Ettenberg Seth | Chief Scientific Officer | 0 0% | $0 | 0 | 6 |
$108,876,545 | 67 | 72.81% | $8.14B | |
$224,382,625 | 44 | 27.62% | $4.87B | |
$477,065,869 | 34 | 82.05% | $5.24B | |
$11,859,102 | 17 | 18.62% | $7.75B | |
$103,944,213 | 17 | 5.95% | $6.87B | |
$74,605,681 | 14 | 47.06% | $5.29B | |
$57,686,748 | 13 | 21.11% | $6.04B | |
$75,296,863 | 13 | 33.79% | $5.52B | |
$91,269,919 | 12 | 12.86% | $5.45B | |
$9,976,473 | 12 | 29.52% | $6.59B | |
$2,477,801 | 11 | 4.98% | $5.55B | |
$35,908,794 | 10 | 126.31% | $5.2B | |
$3,073,199 | 10 | 16.77% | $5.09B | |
$11,898,979 | 10 | 54.58% | $8.16B | |
Cogent Biosciences, Inc. (COGT) | $20,499,451 | 9 | 71.54% | $5.58B |
$55,713,031 | 8 | -0.36% | $6.35B | |
$2,246,813 | 6 | 70.15% | $4.95B | |
$105,414,951 | 5 | 10.07% | $7.74B | |
$41,376,000 | 4 | -12.07% | $6.9B |
| Increased Positions | 127 | +74.71% | 50M | +36.29% |
| Decreased Positions | 74 | -43.53% | 27M | -19.67% |
| New Positions | 40 | New | 13M | New |
| Sold Out Positions | 25 | Sold Out | 6M | Sold Out |
| Total Postitions | 223 | +31.18% | 159M | +16.61% |
| Fmr Llc | $778,463.00 | 14.74% | 22.41M | +5M | +31.21% | 2025-09-30 |
| Blackrock, Inc. | $360,238.00 | 6.82% | 10.37M | +2M | +20.2% | 2025-09-30 |
| Deerfield Management Company, L.P. | $314,505.00 | 5.96% | 9.05M | +6M | +242.89% | 2025-09-30 |
| Fairmount Funds Management Llc | $312,779.00 | 5.92% | 9M | +3M | +44.62% | 2025-09-30 |
| Kynam Capital Management, Lp | $273,966.00 | 5.19% | 7.89M | -606,385 | -7.14% | 2025-09-30 |
| Vanguard Group Inc | $269,501.00 | 5.1% | 7.76M | +1M | +18.93% | 2025-09-30 |
| Commodore Capital Lp | $251,865.00 | 4.77% | 7.25M | +5M | +213.69% | 2025-09-30 |
| Tcg Crossover Management, Llc | $236,168.00 | 4.47% | 6.8M | -166,213 | -2.39% | 2025-09-30 |
| State Street Corp | $165,898.00 | 3.14% | 4.78M | +1M | +41.62% | 2025-09-30 |
| Vr Adviser, Llc | $138,960.00 | 2.63% | 4M | -755,411 | -15.88% | 2025-09-30 |